<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00297180</url>
  </required_header>
  <id_info>
    <org_study_id>KGO105858</org_study_id>
    <nct_id>NCT00297180</nct_id>
  </id_info>
  <brief_title>Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-controlled Study to Evaluate Weight Loss, Safety, Tolerability and Pharmacokinetics in Obese Subjects Following 12-Week Dosing of GW869682, an SGLT2 Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see
      whether enough calories from glucose are excreted in the urine to cause weight loss.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in body weight from baseline to Week 12.</measure>
    <time_frame>from baseline to Week 12.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels of GW869682 at the Week 2 and Week 11.</measure>
    <time_frame>at the Week 2 and Week 11</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">136</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW869682</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Have a BMI within range 30.0 to 40.0kg/m2, inclusive.

          -  Females who meet above criteria must be physiologically incapable of becoming pregnant
             (ie., surgically sterilized, or post-menopausal per protocol definition).

        Exclusion criteria:

          -  History of eating disorders.

          -  Recent history of weight loss or gain.

          -  Had gastrointestinal surgery for treatment of obesity.

          -  Type 1 or type 2 diabetes mellitus.

          -  Have a positive urine drug screen.

          -  Have liver disease.

          -  Have hepatitis B, hepatitis C, or HIV antibodies.

          -  Have a thyroid disorder that is not under control with medication.

          -  Have any disease (such as heart, liver, blood, nervous system, or kidney disease, or
             cancer).

          -  Are unable to participate in an exercise program.

          -  Have used weight loss drugs within 3 months before the start of the study.

          -  Are currently using warfarin, digoxin, oral anti-coagulants (other than aspirin and
             non-steroidal anti-inflammatory drugs), oral or injectable corticosteroids (inhaled &amp;
             intranasal corticosteroids are permitted), or antiretroviral medications.

          -  Used of any investigational drug or device during the study or within 30 days prior to
             1st dosing of study medication.

          -  High or low blood pressure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2006</study_first_submitted>
  <study_first_submitted_qc>February 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2006</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hunger</keyword>
  <keyword>obesity</keyword>
  <keyword>sodium-dependent glucose transporter</keyword>
  <keyword>GW869682</keyword>
  <keyword>body composition</keyword>
  <keyword>SGLT2 inhibitor</keyword>
  <keyword>weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 8, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

